Drugs and the FDA: Safety, Efficacy, and the Public's Trust
暫譯: 藥物與FDA:安全性、有效性與公眾信任

Sekeres, Mikkael A.

  • 出版商: MIT
  • 出版日期: 2024-02-06
  • 售價: $1,210
  • 貴賓價: 9.5$1,150
  • 語言: 英文
  • 頁數: 320
  • 裝訂: Quality Paper - also called trade paper
  • ISBN: 0262548399
  • ISBN-13: 9780262548397
  • 海外代購書籍(需單獨結帳)

相關主題

商品描述

How the FDA was shaped by public health crises and patient advocacy, told against a background of the contentious hearings on the breast cancer drug Avastin.

Food and Drug Administration approval for COVID-19 vaccines and the controversial Alzheimer's drug Aduhelm made headlines, but few of us know much about how the agency does its work. Why is the FDA the ultimate US authority on a drug's safety and efficacy? In Drugs and the FDA, Mikkael Sekeres--a leading oncologist and former chair of the FDA's cancer drug advisory committee--tells the story of how the FDA became the most trusted regulatory agency in the world. It took a series of tragedies and health crises, as well as patient advocacy, for the government to take responsibility for ensuring the efficacy and safety of drugs and medical devices.

Before the FDA existed, drug makers could hawk any potion, claim treatment of any ailment, and make any promise on a label. But then, throughout the twentieth century, the government was forced to take action when children were poisoned by contaminated diphtheria and smallpox vaccines, an early antibiotic contained antifreeze, a drug prescribed for morning sickness in pregnancy caused babies to be born disfigured, and access to AIDS drugs was limited to a few clinical trials while thousands died. Sekeres describes all these events against the backdrop of the contentious 2011 hearings on the breast cancer drug Avastin, in which he participated as a panel member. The Avastin hearings, he says, put to the test a century of the FDA's evolution, demonstrating how its system of checks and balances works--or doesn't work.

商品描述(中文翻譯)

如何在公共衛生危機和病人倡導的背景下,塑造了美國食品藥品監督管理局(FDA),並以有爭議的乳腺癌藥物Avastin的聽證會為背景。

食品藥品監督管理局對COVID-19疫苗和有爭議的阿茲海默症藥物Aduhelm的批准引起了媒體的關注,但我們對該機構的運作方式知之甚少。為什麼FDA是美國對藥物安全性和有效性的最終權威?在《藥物與FDA》中,Mikkael Sekeres——一位領先的腫瘤學家和前FDA癌症藥物諮詢委員會主席——講述了FDA如何成為世界上最受信任的監管機構的故事。這需要一系列的悲劇和健康危機,以及病人的倡導,政府才開始負責確保藥物和醫療設備的有效性和安全性。

在FDA成立之前,藥品製造商可以隨意推銷任何藥水,聲稱可以治療任何疾病,並在標籤上做出任何承諾。然而,在整個二十世紀,當兒童因受污染的白喉和天花疫苗中毒、早期抗生素中含有防凍劑、用於孕期晨吐的藥物導致嬰兒畸形,以及艾滋病藥物的獲取僅限於少數臨床試驗而導致數千人死亡時,政府被迫採取行動。Sekeres在2011年有關乳腺癌藥物Avastin的有爭議的聽證會背景下描述了這些事件,他作為小組成員參加了該聽證會。他表示,Avastin的聽證會考驗了FDA一個世紀的演變,展示了其制衡系統如何運作——或不運作。

作者簡介

Mikkael A. Sekeres is Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, and former Chair of the Oncologic Drugs Advisory Committee of the FDA. A regular contributor to the Well section of the New York Times, he is the author of When Blood Breaks Down: Life Lessons from Leukemia (MIT Press).

作者簡介(中文翻譯)

Mikkael A. Sekeres 是邁阿密大學米勒醫學院西爾維斯特綜合癌症中心的醫學教授及血液學部門主任,並曾擔任美國食品藥品監督管理局(FDA)腫瘤藥物諮詢委員會的主席。他是《紐約時報》健康專欄的定期撰稿人,也是《當血液崩潰:白血病的生活教訓》(MIT Press)的作者。

最後瀏覽商品 (20)